
Sign up to save your podcasts
Or
Every two years, the MS International Federation awards the Charcot Award, recognizing lifetime achievement in outstanding research into the understanding and treatment of MS. My special guest is this year's recipient of the Charcot Award, Professor Alan Thompson, who is being honored for what is truly a remarkable body of work.
We'll also share some encouraging news from the FDA about a biomarker for progressive MS clinical trials.
We'll tell you about the outcome of a study that shows high-efficacy disease-modifying therapies lead to less disability over time for people with relapsing-remitting MS.
And we'll give you the details about how you can participate in a clinical trial that's comparing the safety, efficacy, and cost-effectiveness of autologous hematopoietic stem cell therapy (aHSCT) with high-efficacy disease-modifying therapies.
We have a lot to talk about! Are you ready for RealTalk MS??!
What the Charcot Award is all about :22
FDA supports further development of a biomarker for progressive MS clinical trials 2:10
Study shows high-efficacy DMTs lead to less disability over time 5:58
Recruitment underway for clinical trial comparing stem cell therapy to high-efficacy disease-modifying therapies 9:13
This month's Can-Do MS programs help battle fatigue 12:12
My conversation with Professor Alan Thompson 14:39
Share this episode 31:33
Download the free RealTalk MS app 31:53
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/201
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: [email protected]Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance
FDA Letter of Support to encourage the further use and study of neurofilament light chain as a biomarker for early clinical trials in progressive MS https://www.fda.gov/media/149608/download
STUDY: Long-Term Disability Trajectories in Relapsing Multiple Sclerosis Patients Treated with Early Intensive or Escalation Treatment Strategies https://journals.sagepub.com/doi/full/10.1177/17562864211019574
Beat-MS Studyhttps://www.beat-ms.org
CanDo MS Program Information and Registration https://cando-ms.org/programs
Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms
Download the RealTalk MS App for iOS https://itunes.apple.com/us/app/realtalk-ms/id1436917200
Download the RealTalk MS App for Androidhttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk
Give RealTalk MS a rating and review http://www.realtalkms.com/review
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 201 Guest: Professor Alan Thompson
Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS
Privacy Policy4.7
139139 ratings
Every two years, the MS International Federation awards the Charcot Award, recognizing lifetime achievement in outstanding research into the understanding and treatment of MS. My special guest is this year's recipient of the Charcot Award, Professor Alan Thompson, who is being honored for what is truly a remarkable body of work.
We'll also share some encouraging news from the FDA about a biomarker for progressive MS clinical trials.
We'll tell you about the outcome of a study that shows high-efficacy disease-modifying therapies lead to less disability over time for people with relapsing-remitting MS.
And we'll give you the details about how you can participate in a clinical trial that's comparing the safety, efficacy, and cost-effectiveness of autologous hematopoietic stem cell therapy (aHSCT) with high-efficacy disease-modifying therapies.
We have a lot to talk about! Are you ready for RealTalk MS??!
What the Charcot Award is all about :22
FDA supports further development of a biomarker for progressive MS clinical trials 2:10
Study shows high-efficacy DMTs lead to less disability over time 5:58
Recruitment underway for clinical trial comparing stem cell therapy to high-efficacy disease-modifying therapies 9:13
This month's Can-Do MS programs help battle fatigue 12:12
My conversation with Professor Alan Thompson 14:39
Share this episode 31:33
Download the free RealTalk MS app 31:53
SHARE THIS EPISODE OF REALTALK MS
Just copy this link & paste it into your text or email: https://realtalkms.com/201
ADD YOUR VOICE TO THE CONVERSATION
I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!
Email: [email protected]Phone: (310) 526-2283
And don't forget to join us in the RealTalk MS Facebook group!
LINKS
If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com
National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance
FDA Letter of Support to encourage the further use and study of neurofilament light chain as a biomarker for early clinical trials in progressive MS https://www.fda.gov/media/149608/download
STUDY: Long-Term Disability Trajectories in Relapsing Multiple Sclerosis Patients Treated with Early Intensive or Escalation Treatment Strategies https://journals.sagepub.com/doi/full/10.1177/17562864211019574
Beat-MS Studyhttps://www.beat-ms.org
CanDo MS Program Information and Registration https://cando-ms.org/programs
Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms
Download the RealTalk MS App for iOS https://itunes.apple.com/us/app/realtalk-ms/id1436917200
Download the RealTalk MS App for Androidhttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk
Give RealTalk MS a rating and review http://www.realtalkms.com/review
Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.
RealTalk MS Episode 201 Guest: Professor Alan Thompson
Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS
Privacy Policy1,707 Listeners
502 Listeners
4,930 Listeners
111,827 Listeners
14,233 Listeners
13 Listeners
47 Listeners
309 Listeners
116 Listeners
8,210 Listeners
57,990 Listeners
111 Listeners
10,436 Listeners
10,453 Listeners
3,521 Listeners